Drug interactions with zidovudine phosphorylation in vitro

We have investigated the effect of a range of drugs (some commonly coadministered with zidovudine [ZDV] to human immunodeficiency virus-positive patients) on intracellular phosphorylation of ZDV by stimulated peripheral blood mononuclear cells, Molt 4 cells, and U937 cells in vitro. Of the drugs tested (azoles, antiviral agents, antibiotics, and anticancer agents), only doxorubicin and ribavirin caused inhibition of anabolite formation as measured by high-performance liquid chromatography. This in vitro approach may provide important leads to potential interactions at the phosphorylation level in patients with human immunodeficiency virus disease. It is reassuring that so many commonly administered drugs do not alter ZDV phosphorylation.

[1]  S. Cox,et al.  Intracellular Metabolism of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine in Combination in the Absence and Presence of Ribavirin , 1994 .

[2]  D. Back,et al.  Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. , 1994, British journal of clinical pharmacology.

[3]  R. Ho,et al.  Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells , 1994, Antimicrobial Agents and Chemotherapy.

[4]  N. Beeching,et al.  Zidovudine phosphorylation in HIV‐infected patients and seronegative volunteers , 1994, AIDS.

[5]  D. Back,et al.  The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. , 1994, Biochemical pharmacology.

[6]  L. Mathes,et al.  Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells , 1994, Antimicrobial Agents and Chemotherapy.

[7]  J. Beijnen,et al.  Pharmacokinetic interaction between rifampin and zidovudine , 1993, Antimicrobial Agents and Chemotherapy.

[8]  S. Broder,et al.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.

[9]  J. Beijnen,et al.  Drug interactions with zidovudine. , 1993, AIDS.

[10]  J. Sommadossi.  Nucleoside analogs: similarities and differences. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Shelton,et al.  Comparative Pharmacokinetics of Antiviral Nucleoside Analogues , 1993, Clinical pharmacokinetics.

[12]  B. Gazzard,et al.  Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients , 1992, Antimicrobial Agents and Chemotherapy.

[13]  D. Smith,et al.  The pharmacokinetics of oral itraconazole in AIDS patients , 1992, The Journal of pharmacy and pharmacology.

[14]  Elias S. J. Arnér,et al.  Thymidine and 3'-azido-3'-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways. , 1992, The Journal of biological chemistry.

[15]  R. Diasio,et al.  Clinical pharmacokinetics of 3′‐azido‐3′‐deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′‐amino‐3′‐deoxythymidine , 1992, Clinical pharmacology and therapeutics.

[16]  R. Bevan,et al.  Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells. , 1991, Molecular pharmacology.

[17]  J. Weinstein,et al.  Effects of thymidine and uridine on the phosphorylation of 3'-azido-3'-deoxythymidine (zidovudine) in human mononuclear cells , 1991, Antimicrobial Agents and Chemotherapy.

[18]  K. Squires,et al.  Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. , 1988, The American journal of medicine.

[19]  E. De Clercq,et al.  Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro , 1987, Antimicrobial Agents and Chemotherapy.

[20]  J. Longstreth,et al.  Ribavirin disposition in high‐risk patients for acquired immunodeficiency syndrome , 1987, Clinical pharmacology and therapeutics.

[21]  R. Schooley,et al.  Ribavirin antagonizes the effect of azidothymidine on HIV replication , 1987, Science.

[22]  H. Balfour,et al.  Human pharmacokinetics of the antiviral drug DHPG , 1986, Clinical pharmacology and therapeutics.

[23]  J. D. Karkas,et al.  9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Whitley,et al.  Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals. , 1982, The American journal of medicine.

[25]  M. Gibaldi,et al.  Pharmacokinetics of Erythromycin in Normal and Alcoholic Liver Disease Subjects , 1982, Journal of clinical pharmacology.

[26]  T. Blaschke,et al.  Disposition of ketoconazole, an oral antifungal, in humans , 1982, Antimicrobial Agents and Chemotherapy.

[27]  Y. Cheng,et al.  Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases , 1981, Antimicrobial Agents and Chemotherapy.

[28]  S. Eksborg,et al.  Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. , 1979, Journal of chromatography.

[29]  C. Heusghem,et al.  Pharmacokinetic Studies of Co‐Trimoxazole in Man After Single and Repeated Doses , 1974, Journal of clinical pharmacology.